Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
112.35
-0.88 (-0.78%)
After Hours: 112.35 0.00 (0.00%)
Apr 28, 4:21PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 110.65 - 113.89
52 week 96.63 - 177.93
Open 113.00
Vol / Avg. 214,987.00/328,623.00
Mkt cap 2.78B
P/E     -
Div/yield     -
EPS -16.74
Shares 24.83M
Beta -1.99
Inst. own 86%
Jul 19, 2017
Intercept Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 4, 2017
Q1 2017 Intercept Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 4, 2017
Q1 2017 Intercept Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Apr 4, 2017
Intercept Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
Mar 21, 2017
Intercept Pharmaceuticals Inc at Oppenheimer Healthcare Conference - Webcast
Mar 6, 2017
Intercept Pharmaceuticals Inc at Cowen Health Care Conference
Feb 23, 2017
Intercept Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference
Feb 23, 2017
Q4 2016 Intercept Pharmaceuticals Inc Earnings Release
Feb 23, 2017
Q4 2016 Intercept Pharmaceuticals Inc Earnings Call
Feb 10, 2017
Intercept Pharmaceuticals Inc Conference Call to discuss update on Phase 3 REGENERATE Trial of Obeticholic Acid (OCA)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -869.36% -1654.56%
Operating margin -825.66% -1613.31%
EBITD margin - -1417.61%
Return on average assets -62.07% -59.19%
Return on average equity -131.94% -90.03%
Employees 456 -
CDP Score - -

Address

450 W 15th St Ste 505
NEW YORK, NY 10011-7082
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Officers and directors

Paolo Fundaro Independent Chairman of the Board
Age: 42
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Sandip S. Kapadia Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Lisa Bright President, International
Age: 48
Bio & Compensation  - Reuters
Jerome Benedict Durso Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 61
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Business and Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Luca Benatti Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Gino Santini Independent Director
Age: 59
Bio & Compensation  - Reuters